Athanor Capital’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Athanor Capital’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-147,800	Closed	-$1.43M	–	166
2021 Q3	$1.43M	Hold	147,800	–	–	0.19%	116
2021 Q2	$1.43M	Buy	+147,800	New	+$1.45M	0.05%	199

Other funds holding EBAC

Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Athanor Capital's EBAC Position: Q4 2021 in Review

Athanor Capital sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q4 2021, closing a stake of 147,800 shares — an estimated $1.43M sold.

Athanor Capital first reported a position in EBAC in Q2 2021 and held it in 2 quarters. The position peaked at $1.43M in Q3 2021. 45 funds tracked by Wall St. Rank hold EBAC as of Q4 2021.

Athanor Capital reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q4 2021 after selling out during the quarter.
Athanor Capital sold 147,800 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q4 2021, an estimated $1.43M.
Athanor Capital first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 2 quarters.
Athanor Capital's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $1.43M in Q3 2021.
45 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q4 2021.

Based on Athanor Capital's 13F filing for Q4 2021, filed 14 Feb 2022.